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Introduction 
Necrobiosis lipoidica is a rare, chronic, cutaneous 
granulomatous disease that primarily affects young 
and middle-aged adults, with an increased 
predilection for females [1, 2]. It is often associated 
with diabetes mellitus and was called “necrobiosis 
lipoidica diabeticorum” in the past. This terminology 
was later changed to necrobiosis lipoidica and 
occurs in the absence of diabetes mellitus, although 
it is worth noting that necrobiosis lipoidica may 
precede a diagnosis of diabetes mellitus and occurs 
in about 0.3-1.2 percent of individuals with diabetes 
mellitus [1, 3, 4]. An association of necrobiosis 
lipoidica with other systemic diseases such as 
thyroiditis, inflammatory bowel disease, sarcoidosis, 
obesity, and cardiovascular disease has also been 
found and squamous cell cancer can occur in 
necrobiosis lipoidica lesions [5-7]. The pathogenesis 
of necrobiosis lipoidica is unclear but multiple  
theories exist, including impaired neutrophil 
migration, collagen defects, immunoglobulin 
deposition, and microangiopathy secondary to 
blood vessel glycoprotein deposition [1, 8-12]. 
Lesions often initially present as asymptomatic 
papules and nodules and over time, evolve into well-
demarcated yellow brown plaques with violaceous 
borders, central waxy atrophic appearance, and 
telangiectasias [13]. Lesions can ulcerate and 
become painful in some individuals and 
koebnerization can also occur [1, 2, 14-16]. Although 
the pretibial area is most often commonly affected, 
necrobiosis lipoidica can occur on other parts of the 
body as well [13]. Histological findings typically show 
a diffuse palisaded and interstitial granulomatous 
dermatitis with focal connective tissue degeneration 
and vascular changes, but the appearance can vary 
throughout the course of the disease and among 
different patients [1, 17]. Treatment of necrobiosis 
lipoidica is often challenging and when lesions do 
resolve, post-inflammatory and atrophic changes 
can still persist [13]. The quality of life of individuals 
with this disease is significantly affected as a result of 
its recalcitrant nature. 
 
Case Synopsis 
A 29-year-old woman with a history of poorly 
controlled diabetes, depression, hypertension, and a 
one pack-per-day smoking history presented on 
initial consultation to our dermatology clinic with 
painful skin lesions on her lower legs that had started 
off as a small spot on her left shin four years prior. 
Since the initial lesion she progressively developed 
more and larger plaques on both lower legs, which 
Abstract 
Necrobiosis lipoidica is a chronic granulomatous 
disease of unknown etiopathogenesis, which is often 
difficult to treat. While data from randomized 
controlled trials for the treatment of necrobiosis 
lipoidica is lacking, several treatments of varying 
efficacy for necrobiosis lipoidica have been reported 
in the scientific literature. We present a case of a 29-
year-old female with uncontrolled diabetes and 
treatment-resistant necrobiosis lipoidica which was 
responsive to ustekinumab. 
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would ulcerate, bleed, and drain pus (Figure 1A, B). 
She had been diagnosed with necrobiosis lipoidica 
based on a biopsy done by an outside dermatology 
office a few months prior. Her previous treatment 
course included multiple topical, systemic, and 
intralesional steroids, topical tacrolimus, oral 
antibiotics and antifungals, and 
hydroxychloroquine, which had been unsuccessful 
at resolving the lesions. For several months after 
presentation to our office, the patient’s treatment 
plan included many different medications including 
an increase in hydroxychloroquine, as well as topical 
clobetasol occlusion wraps. Phototherapy was 
deferred owing to distance of travel for the patient. 
Pentoxifylline was started but discontinued after the 
patient reported gastrointestinal side effects. 
Adalimumab was initiated but then discontinued 
because of the development of an abdominal rash 
and urticarial plaques at the injection site. The 
patient also continued to develop new plaques 
despite treatment with pentoxifylline and 
adalimumab. Intralesional triamcinolone injections 
provided partial improvement, but her condition 
was complicated by several pseudomonal bacterial 
infections, requiring several courses of antibiotics. 
Given minimal response to the aforementioned 
treatments, ustekinumab was initiated in addition to 
the continuation of hydroxyquinone and topical 
clabetasol occlusion wraps. The ustekinumab was 
dosed at 90mg every two months as this was 
successful in another patient [18]. After a few months 
of therapy with ustekinumab, the patient’s skin 
lesions improved, despite being hospitalized once 
for cellulitis (Figure 1C, D). It was decided that with 
any future intralesional triamcinolone injections she 
would be dosed prophylactically with antibiotics to 
prevent secondary bacterial infections. 
 
Case Discussion 
Many of the challenges in treating necrobiosis 
lipoidica are likely related to the unclear 
pathophysiology of the disease. The broad spectrum 
of histological findings between individuals suggests 
a multifactorial etiology and may be the reason for 
diverse treatment responses [17]. Histopathological 
findings can also differ at different times of the 
course of the disease, as it did in our patient, with an 
earlier biopsy showing more of a non-specific 
reactive process. Diagnosis and effective treatment 
were delayed as a result. Our patient’s risk factors of 
smoking, hypertension, uncontrolled diabetes, and 
history of repeated wound infections also likely 
played a role in poor treatment response. 
The scientific literature for the treatment of 
necrobiosis lipoidica mostly consists of case reports 
and small clinical trials [19]. Topical, systemic, and 
intralesional steroids are often used as a first line 
treatment with varying responses. [20-22]. Topical 
tacrolimus, PUVA, photodynamic therapy, 
 
 
Figure 1. Lesions of the right lower leg A) and left lower leg B) on 
the patient’s initial visit to our office. Post inflammatory changes 
and improvement of the erythema and ulcerations of the right 
lower leg C) and left lower leg D) after 6 weeks of treatment with 
ustekinumab (7 months after the initial visit to our office). 
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antimalarials, immunomodulators, biologic agents, 
IVIG, topical tretinoin, hyperbaric oxygen therapy, 
and cutaneous blood flow modulators are just some 
of the treatments that have all been reported [23-34]. 
Whether diabetic glycemic control improves 
necrobiosis lipoidica has not yet been supported by 
studies, but could theoretically help wound healing, 
improve vascular function, and prevent 
superinfection [35]. Emphasizing smoking cessation 
and avoidance of trauma can also help reduce 
complications [35, 36]. 
Anti-TNF agents, in particular, are effective in 
treating granulomatous disease and have been 
successfully used as monotherapy in treating 
ulcerating necrobiosis lipoidica [13, 29, 37]. Given 
our patient’s adverse reaction to adalimumab and 
treatment failure for most therapies, we elected to 
utilize ustekinumab, an IL12 and IL23 inhibitor 
typically used to treat psoriasis [38]. Ustekinumab 
was successfully used for one case of necrobiosis 
lipoidica in our practice in an individual without 
diabetes in the past [18]. The intention behind using 
ustekinumab was to target the Th1 pathway to limit 
granuloma formation. A proposed mechanism by 
which ustekinumab treats necrobiosis lipoidica may 
be related to its ability to target the Th1 pathway 
through IL12 inhibition. Th1 cells, which require IL12,  
interact with macrophages in a CD40-CD40L-
dependent manner, leading to IFN secretion. 
Interferon  binds to the macrophage receptors, 
activating them and promoting TNF formation, 
leading to granuloma formation. Interleukin 23 
inhibition of Th17 cells by ustekinumab may also 
account for its effectiveness in necrobiosis lipoidica, 
as these cells have been found in skin lesions of 
necrobiosis lipoidica [39-41].  
 
Conclusion 
Necrobiosis lipoidica is a complex disease of 
multifactorial etiology. A tailored treatment 
approach for the individual is necessary. 
Ustekinumab may be an effective treatment for 
treatment-resistant necrobiosis lipoidica. Given 
challenges in treating necrobiosis lipoidica and 
limited data on effective therapies, further clinical 
studies for the use of ustekinumab in the treatment 
of necrobiosis lipoidica are required. 
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